Aim. To determine if hormonal treatment induces apoptosis in uterine fibroids. Methods. Immunohistochemical examination of fibroid tissue, using avidin-biotin complex and cleaved caspase-3 antibody for detecting apoptosis, was performed in premenopausal women who underwent 12-week treatment with oral SPRM (6 patients with 5 mg and 5 patients with 10 mg of ulipristal acetate per day) or gonadoliberin agonist (GnRHa, 17 patients) and subsequent myomectomy or hysterectomy for symptomatic uterine fibroids. Ten patients with no presurgical hormonal treatment were used as controls. Results. Apoptosis was present in a significantly higher proportion of patients treated with ulipristal acetate compared to GnRHa (P = 0.01) and to patients with no hormonal treatment (P = 0.01). In contrast to an AI of 158.9 in SPRM patients, the mean AI was 27.5 and 2.0 in GnRHa and control groups, respectively. No statistical difference in the AI was observed between the two groups of patients treated with ulipristal acetate (5 mg or 10 mg). Conclusion. Treatment with ulipristal acetate induces apoptosis in uterine fibroid cells. This effect of SPRM may contribute to their positive clinical effect on uterine fibroids.

Department of Obstetrics and Gynaecology 1st Faculty of Medicine Charles University Prague Apolinarska 18 128 00 Prague Czech Republic

Zobrazit více v PubMed

Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstetrics and Gynecology. 2004;104(2):393–406. PubMed

Arici A, Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-β1 in human myometrium and leiomyoma. American Journal of Obstetrics and Gynecology. 2003;188(1):76–83. PubMed

Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstetrics and Gynecology. 1997;90(6):967–973. PubMed

Maruo T, Matsuo H, Shimomura Y, et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids. 2003;68(10–13):817–824. PubMed

Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstetrics and Gynecology Clinics of North America. 2006;33(1):41–58. PubMed

Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. American Journal of Human Genetics. 2003;73(1):95–106. PubMed PMC

Walker CL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Progress in Hormone Research. 2002;57:277–294. PubMed

Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertility and Sterility. 2011;95(2):767.e2–772.e2. PubMed PMC

Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism. 2008;93(12):4664–4671. PubMed

Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. Journal of Clinical Endocrinology and Metabolism. 2006;91(4):1296–1304. PubMed

Donnez J, Tatarchuk TF, Bouchard P. Ulipristal acetate versus placebo for fibroid treatment prior to surgery. The New England Journal of Medicine. 2012;366(5):409–420. PubMed

Higham JM, O’Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology. 1990;97(8):734–739. PubMed

Janssen CAH, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstetrics and Gynecology. 1995;85(6):977–982. PubMed

Burroughs KD, Fuchs-Young R, Davis B, Walker CL. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biology of Reproduction. 2000;63(5):1322–1330. PubMed

Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Human Reproduction. 2010;25(3):642–653. PubMed

Liu WM. Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic leiomyomas. Journal of the American Association of Gynecologic Laparoscopists. 2000;7(1):125–129. PubMed

Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. The Lancet. 1995;346(8976):671–672. PubMed

Recaldini C, Carrafiello G, Laganà D, et al. Percutaneous sonographically guided radiofrequency ablation of medium-sized fibroids: feasibility study. American Journal of Roentgenology. 2007;189(6):1303–1306. PubMed

Stewart EA, Gedroyc WMW, Tempany CMC, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. American Journal of Obstetrics and Gynecology. 2003;189(1):48–54. PubMed

Eisinger SH, Meldrum S, Fiscella K, Le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstetrics and Gynecology. 2003;101(2):243–250. PubMed

Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, “add-back” steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-β expression. Molecular Human Reproduction. 2002;8(12):1071–1078. PubMed

Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75(6):S99–S103. PubMed

Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Current Opinion in Obstetrics and Gynecology. 2004;16(3):239–243. PubMed

Rackow BW, Arici A. Options for medical treatment of myomas. Obstetrics and Gynecology Clinics of North America. 2006;33(1):97–113. PubMed

Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertility and Sterility. 2003;79(3):628–631. PubMed

De Leo V, Morgante G, La Marca A, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Safety. 2002;25(11):759–779. PubMed

Golan A, Bukovsky I, Pansky M, Schneider D, Weinraub Z, Caspi E. Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata. Human Reproduction. 1993;8(3):450–452. PubMed

Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. An International Journal of Obstetrics and Gynaecology. 2002;109(10):1097–1108. PubMed

Manyonda I, Sinthamoney E, Belli AM. Controversies and challenges in the modern management of uterine fibroids. An International Journal of Obstetrics and Gynaecology. 2004;111(2):95–102. PubMed

Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumor Biology. 1995;16(4):254–260. PubMed

Chrapusta S, Sieinski W, Konopka B, Szamborski J, Paszko Z. Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle. European Journal of Gynaecological Oncology. 1990;11(5):381–387. PubMed

Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. American Journal of Obstetrics and Gynecology. 1989;160(3):637–641. PubMed

DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids. 2003;68(10–13):1019–1032. PubMed

Murphy AA, Morales AJ, Kettel LM, Yen SSC. Regression of uterine leiomyomata to the antiprogesterone RU486: dose- response effect. Fertility and Sterility. 1995;64(1):187–190. PubMed

Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2009;49(1):77–83. PubMed

Wilkens J, Williams ARW, Chwalisz K, Han C, Cameron IT, Critchley HOD. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction. 2009;24(5):1036–1044. PubMed

Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction. 2007;22(6):1696–1704. PubMed

Maruo T, Ohara N, Yoshida S, et al. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception. 2010;82(5):435–441. PubMed

Yin P, Lin Z, Cheng YH, et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. Journal of Clinical Endocrinology and Metabolism. 2007;92(11):4459–4466. PubMed

Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Seminars in Reproductive Medicine. 2010;28(3):260–273. PubMed

Martel KM, Ko AC, Christman GM, Stribley JM. Apoptosis in human uterine leiomyomas. Seminars in Reproductive Medicine. 2004;22(2):91–103. PubMed

Duan WR, Gamer DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EAG. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. Journal of Pathology. 2003;199(2):221–228. PubMed

Donnez J, Tomaszewski J, Vázquez F. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. The New England Journal of Medicine. 2012;366:421–432. PubMed

Committee on Gynecologic Practice. Uterine artery embolization. Obstetrics & Gynecology. 2004;103:403–404. PubMed

Kuzel D, Mara M, Horak P, et al. Comparative outcomes of hysteroscopic examinations performed after uterine artery embolization or laparoscopic uterine artery occlusion to treat leiomyomas. Fertility and Sterility. 2011;95(6):2143–2145. PubMed

Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertility and Sterility. 2010;94(1):324–330. PubMed

Park KH, Kim JY, Shin JS, et al. Treatment outcomes of uterine artery embolization and laparoscopic uterine artery ligation for uterine myoma. Yonsei Medical Journal. 2003;44(4):694–702. PubMed